Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by Barclays PLC

Barclays PLC lessened its position in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 24.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 319,589 shares of the biotechnology company's stock after selling 102,720 shares during the quarter. Barclays PLC owned about 0.11% of Exelixis worth $8,294,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the company. Covestor Ltd lifted its holdings in shares of Exelixis by 5.7% in the 3rd quarter. Covestor Ltd now owns 6,335 shares of the biotechnology company's stock valued at $164,000 after acquiring an additional 341 shares during the last quarter. Resonant Capital Advisors LLC raised its position in Exelixis by 3.6% during the second quarter. Resonant Capital Advisors LLC now owns 13,746 shares of the biotechnology company's stock valued at $309,000 after purchasing an additional 477 shares during the period. Cornercap Investment Counsel Inc. lifted its stake in shares of Exelixis by 1.1% in the 2nd quarter. Cornercap Investment Counsel Inc. now owns 50,497 shares of the biotechnology company's stock valued at $1,135,000 after purchasing an additional 539 shares during the last quarter. Creative Planning boosted its holdings in shares of Exelixis by 0.8% in the 2nd quarter. Creative Planning now owns 71,700 shares of the biotechnology company's stock worth $1,611,000 after purchasing an additional 548 shares during the period. Finally, Advisors Asset Management Inc. increased its position in shares of Exelixis by 3.2% during the 3rd quarter. Advisors Asset Management Inc. now owns 19,853 shares of the biotechnology company's stock valued at $515,000 after purchasing an additional 609 shares during the last quarter. Institutional investors own 85.27% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on EXEL shares. Stifel Nicolaus lifted their price objective on shares of Exelixis from $26.00 to $30.00 and gave the stock a "hold" rating in a research note on Wednesday, October 16th. JMP Securities reiterated a "market outperform" rating and set a $29.00 price target on shares of Exelixis in a report on Friday, October 11th. Truist Financial boosted their target price on Exelixis from $33.00 to $38.00 and gave the company a "buy" rating in a research report on Wednesday, October 30th. Bank of America lowered Exelixis from a "buy" rating to a "neutral" rating and raised their price target for the stock from $35.00 to $39.00 in a research note on Tuesday. Finally, TD Cowen upped their price objective on Exelixis from $27.00 to $34.00 and gave the company a "buy" rating in a research report on Monday, October 21st. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $31.88.

Exelixis Stock Performance

Shares of EXEL traded down $1.03 during trading hours on Wednesday, hitting $33.66. The stock had a trading volume of 2,638,784 shares, compared to its average volume of 2,056,410. The firm has a market capitalization of $9.61 billion, a price-to-earnings ratio of 21.58, a PEG ratio of 0.89 and a beta of 0.52. The firm has a 50-day moving average price of $33.04 and a 200 day moving average price of $27.38. Exelixis, Inc. has a fifty-two week low of $19.20 and a fifty-two week high of $36.97.

Exelixis (NASDAQ:EXEL - Get Free Report) last posted its earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 EPS for the quarter, beating analysts' consensus estimates of $0.36 by $0.04. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. The firm had revenue of $539.50 million for the quarter, compared to analysts' expectations of $490.31 million. During the same period last year, the firm earned $0.10 EPS. The company's quarterly revenue was up 14.3% on a year-over-year basis. As a group, analysts predict that Exelixis, Inc. will post 1.69 EPS for the current fiscal year.

Insider Activity

In related news, EVP Patrick J. Haley sold 41,588 shares of the stock in a transaction on Monday, November 18th. The stock was sold at an average price of $34.36, for a total value of $1,428,963.68. Following the completion of the transaction, the executive vice president now directly owns 288,665 shares of the company's stock, valued at approximately $9,918,529.40. This represents a 12.59 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Jeffrey Hessekiel sold 25,000 shares of the firm's stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $26.38, for a total value of $659,500.00. Following the completion of the transaction, the executive vice president now owns 605,325 shares in the company, valued at $15,968,473.50. The trade was a 3.97 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 339,736 shares of company stock worth $11,508,610 in the last quarter. Corporate insiders own 2.85% of the company's stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.